Yuan Ji

Yuan Ji, PhD, FACMG, Executive MBA, MS

Languages spoken: English, Chinese

Academic Information

Departments Primary - Pathology

Education History

Certification University of Utah
 Post-Master Certificate
University of Utah
 Executive MBA
Fellowship Mayo Clinic
 Fellow
John Hopkins - Jackson Laboratory
 Certificate
Post Graduate Training Mayo Clinic
 Certificate
Mayo Clinic
 Fellow
Research Fellow Mayo Clinic
 Postdoctoral Research Fellow
Mayo Clinic
 PhD
Graduate Training Xiamen University
 MS
Xiamen University
 BS

Selected Publications

Journal Article

  1. Pratt VM, Tredici ALD, Hachad H, Ji Y, Kalman L, Scott SA, Weck KE (02/21/2018). CYP2C19 Genotyping Recommendations: A Report of the Association for Molecular Pathology. J Mol Diagn, 20(3), 269-276.
  2. Shen W, Young BA, Bosworth M, Wright KE, Lamb AN, Ji Y (02/05/2018). Prenatal detection of uniparental disomy of chromosome 2 carrying a CHRND pathogenic variant that causes lethal multiple pterygium syndrome. Clin Genet.
  3. Wu JH, Tian W, Tian GL, Sumner K, Hutchinson D, Ji Y (01/01/2018). A systematic investigation of PIK3CA mutations in isolated macrodactyly: indication for accurate classification, diagnosis, and novel therapeutics. J Hand Surg Eur Vol.
  4. Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, Peterson LM, Veldhuizen TL, Fadra N, Peterson SE, Lagerstedt SA, Train LJ, Baudhuin LM, Klee EW, Ferber MJ, Bielinski SJ, Caraballo PJ, Weinshilboum RM, Black JL 3rd (2016). Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol Diagn, 18(3), 438-45. (Read full article)
  5. Lindor NM, Schahl KA, Johnson KJ, Hunt KS, Mensink KA, Wieben ED, Klee E, Black JL, Highsmith WE Jr, Thibodeau SN, Ferber MJ, Aypar U, Ji Y, Graham RP, Fiksdal AS, Sarangi V, Ormond K, Riegert-Johnson DL, McAllister TM, Farrugia G, McCormick JB (2015). Whole Exome Sequencing of 10 Scientists: Evaluation of Process and Outcomes. Mayo Clin Proc, 90(10), 1327-37.
  6. Hicks JK, Bishop JR, Sangkuhl K, Mller DJ, Ji Y, Leckband SG, Leeder JS, Chiulli DL, Graham RL, LLerena A, Skaar TC, Klein TE, Caudle KE, Gaedigk A (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther, 98(2), 127-34.
  7. Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmoller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE, Weinshilboum R (2015). The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry, 5, e553. (Read full article)
  8. Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K, Mushiroda T, Kamatani N, Ogburn E, Hall-Flavin D, Flockhart D, Nakamura Y, Mrazek DA, Weinshilboum RM (2014). Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol, 78(2), 373-83. (Read full article)
  9. Ji Y, Biernacka JM, Hebbring S, Chai Y, Jenkins GD, Batzler A, Snyder KA, Drews MS, Desta Z, Flockhart D, Mushiroda T, Kubo M, Nakamura Y, Kamatani N, Schaid D, Weinshilboum RM, Mrazek DA (2013). Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J, 13(5), 456-63. (Read full article)
  10. Ellsworth KA, Moon I, Eckloff BW, Fridley BL, Jenkins GD, Batzler A, Biernacka JM, Abo R, Brisbin A, Ji Y, Hebbring S, Wieben ED, Mrazek DA, Weinshilboum RM, Wang L (2013). FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics, 23(3), 156-66. (Read full article)
  11. Ji Y, Nordgren KK, Chai Y, Hebbring SJ, Jenkins GD, Abo RP, Peng Y, Pelleymounter LL, Moon I, Eckloff BW, Chai X, Zhang J, Fridley BL, Yee VC, Wieben ED, Weinshilboum RM (2012). Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation. Drug Metab Dispos, 40(10), 1984-92. (Read full article)
  12. Thorn CF, Ji Y, Weinshilboum RM, Altman RB, Klein TE (2012). PharmGKB summary: very important pharmacogene information for GSTT1. Pharmacogenet Genomics, 22(8), 646-51. (Read full article)
  13. Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Fridley B, Schaid D, Kamatani N, Nakamura Y, Kubo M, Mushiroda T, Kaddurah-Daouk R, Mrazek DA, Weinshilboum RM (2012). Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics, 22(4), 247-53. (Read full article)
  14. Fridley BL, Jenkins GD, Batzler A, Wang L, Ji Y, Li F, Weinshilboum RM (2012). Multivariate models to detect genomic signatures for a class of drugs: application to thiopurines pharmacogenomics. Pharmacogenomics J, 12(2), 105-10. (Read full article)
  15. Hebbring SJ, Chai Y, Ji Y, Abo RP, Jenkins GD, Fridley B, Zhang J, Eckloff BW, Wieben ED, Weinshilboum RM (2012). Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization. J Neurochem, 120(6), 881-90. (Read full article)
  16. Ji Y, Biernacka J, Snyder K, Drews M, Pelleymounter LL, Colby C, Wang L, Mrazek DA, Weinshilboum RM (2012). Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics J, 12(1), 78-85. (Read full article)
  17. Fridley BL, Batzler A, Li L, Li F, Matimba A, Jenkins GD, Ji Y, Wang L, Weinshilboum RM (2011). Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics, 21(11), 701-12. (Read full article)
  18. Moyer AM, Fridley BL, Jenkins GD, Batzler AJ, Pelleymounter LL, Kalari KR, Ji Y, Chai Y, Nordgren KK, Weinshilboum RM (2011). Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study. Toxicol Sci, 120(1), 33-41. (Read full article)
  19. Feng Q, Kalari K, Fridley BL, Jenkins G, Ji Y, Abo R, Hebbring S, Zhang J, Nye MD, Leeder JS, Weinshilboum RM (2011). Betaine-homocysteine methyltransferase: human liver genotype-phenotype correlation. Mol Genet Metab, 102(2), 126-33. (Read full article)
  20. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM (2011). Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther, 89(1), 97-104. (Read full article)
  21. Li F, Fridley BL, Matimba A, Kalari KR, Pelleymounter L, Moon I, Ji Y, Jenkins GD, Batzler A, Wang L, Weinshilboum RM (2010). Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos, 38(12), 2329-38. (Read full article)
  22. Zhang J, Ji Y, Moon I, Pelleymounter LL, Ezequel Salavaggione O, Wu Y, Jenkins GD, Batzler AJ, Schaid DJ, Weinshilboum RM (2009). Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies. Pharmacogenet Genomics, 19(8), 577-87. (Read full article)
  23. Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon JM, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Ko Y, Bruning T, Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R (2008). Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res, 68(14), 5997-6005. (Read full article)
  24. Ji Y, Snyder EM, Fridley BL, Salavaggione OE, Moon I, Batzler A, Yee VC, Schaid DJ, Joyner MJ, Johnson BD, Weinshilboum RM (2008). Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release. Physiol Genomics, 33(3), 323-32. (Read full article)
  25. Ji Y, Moon I, Zlatkovic J, Salavaggione OE, Thomae BA, Eckloff BW, Wieben ED, Schaid DJ, Weinshilboum RM (2007). Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics. J Pharmacol Exp Ther, 322(2), 529-40. (Read full article)
  26. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, Weinshilboum RM (2006). Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res, 12(6), 1794-803. (Read full article)
  27. Ji Y, Salavaggione OE, Wang L, Adjei AA, Eckloff B, Wieben ED, Weinshilboum RM (2005). Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. J Neurochem, 95(6), 1766-76. (Read full article)
  28. Wu Q, Ji Y, Zhang MQ, Chen YQ, Chen F, Shi DL, Zheng ZH, Huang YJ, Su WJ (2003). Role of tumor metastasis suppressor gene KAI1 in digestive tract carcinomas and cancer cells. Cell Tissue Res, 314(2), 237-49. (Read full article)
  29. Ji Y, Qiao W (2002). New members of p53 family, p63 and p73. Chin J Cancer, 21, 1164-7.

Review

  1. Ji Y, Si C, co-first author, McMillin G, Lyon E (04/23/2018). Clinical pharmacogenetics testing in the era of next generation sequencing: challenges and opportunities for precision medicine. [Review]. Expert Rev Mol Diagn.

Book Chapter

  1. Ji Y (2018). Pharmacogenomics: The use of pharmacogenomics in oncology. In Gregory J. Tsongalis, Ann Moyer (Eds.), Advances in Molecular Pathology (1.1, pp. 115-124). Philadelphia, PA: ELSEVIER.

Other

  1. Dai N, Foldager L, Gallego JA, Hack LM, Ji Y, Lett TA, Liu BC, Loken EK, Mandelli L, Mehta D, Power RA, Sprooten E, Stephens SH, Paska AV, Yan J, Zai CC, Zai G, Zhang-James Y, OShea A, Delisi LE (2012). Summaries from the XIX World Congress of Psychiatric Genetics, Washington, DC, September 10-14, 2011. Am J Med Genet B Neuropsychiatr Genet (159B(1), pp. 128-9). United States. (Read full article)